10

Jun2020

Amendment to the Patented Medicines Regulations Published in Canada Gazette II

As expected, amendments to the Patented Medicines Regulations (“Regulations”) were published in Canada Gazette II this morning.  The amendments officially change the coming into force date of the new amending Regulation to January 1, 2021.  These Regulations were originally published in Canada Gazette II on August 21, 2020 with an ... Read More

01

Jun2020

PMPRB Guidelines and Regulations Update

PMPRB Guidelines and Regulations Update As first disclosed by PDCI last week, the PMPRB Board Chair officially confirmed that the amended Patented Medicines Regulations (“Regulations”) will now come into force on January 1, 2021.  These Regulations were published in Canada Gazette II in August 2019 with ... Read More

29

May2020

Delay of Implementation of PMPRB Amended Regulations to January 1, 2021

PDCI Market Access understands from multiple sources that Health Canada is reaching out to stakeholder groups today to confirm the delay of the implementation of the PMPRB amended Regulations to January 1, 2021. Official publication of the delay in Canada Gazette to follow (likely in CG2 on June ... Read More

05

May2020

TargetPharma – CADTH Pharmaceutical Review Update 15

REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ... Read More

16

Apr2020

PDCI Launches 2020 Private Payer PLA Study

PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study! The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders ... Read More

14

Apr2020

Impact of COVID-19-Related Layoffs on Patients’ Access to Group Insurance

Bryan Ferguson, Editor, Insights Within 1-2 weeks, 1 million people laid off in March will begin to lose their health benefits.Laid-off patients who previously had access to drug insurance will now find themselves with no coverage or, if coverage continues, with reduced financial means to afford copayments and ... Read More

06

Apr2020

PDCI Market Access Inc. Welcomes Mark Fleming as a Strategic Advisor

PDCI Market Access Inc. (PDCI), Canada’s leading pricing, reimbursement and health economics consultancy, is pleased to announce its strategic partnership with Mark Fleming.  Mark is joining PDCI as Strategic Advisor supporting PDCI’s pricing, market access and policy research activities.   ... Read More

31

Mar2020

PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers

We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc. The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ... Read More

19

Mar2020

PMPRB Has Now Published Submissions Received as Part of its Draft Guidelines Consultation

The full list of submissions can be found here under the Submissions tab at the bottom of the page. Background: On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. The PMPRB ... Read More

16

Mar2020

PDCI Business Operations: Business [Almost] as Usual!

Good Afternoon, At PDCI Market Access Inc. (“PDCI”) we are committed to providing high quality services and deliverables to our clients. We also recognize the important responsibility we all have to prevent the spread of the COVID-19 outbreak. Based on the information received to date, we are currently implementing the following accommodations ... Read More